- 4D Molecular Therapeutics Inc 4D-150 Phase 2 PRISM Clinical Data Call TranscriptFeb 05, 2024
- 4D Molecular Therapeutics Inc 4D-710 Phase 1/2 AEROW Interim Clinical Data and Program Update Call TranscriptNov 01, 2023
- 4D Molecular Therapeutics Inc at Chardan Genetic Medicines Conference TranscriptOct 02, 2023
- 4D Molecular Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- 4D Molecular Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- 4D Molecular Therapeutics Inc 4D-710 Phase 1/2 AEROW Interim Clinical Data Call TranscriptJun 07, 2023
- 4D Molecular Therapeutics Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) TranscriptMay 30, 2023
- 4D Molecular Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- 4D Molecular Therapeutics Inc 4D-150 Phase 1/2 PRISM Interim Clinical Data - Corporate Call TranscriptApr 27, 2023
- 4D Molecular Therapeutics Inc 4D-310 Phase 1/2 Interim Clinical Data Call TranscriptFeb 22, 2023
- 4D Molecular Therapeutics Inc Phase 1/2 Clinical Trial of 4D-150 for Wet AMD - Corporate Call TranscriptNov 14, 2022
- 4D Molecular Therapeutics Inc Interim Clinical Data Presented at NACFC - Corporate Call TranscriptNov 03, 2022
- 4D Molecular Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- 4D Molecular Therapeutics Inc at Bank of America Healthcare Conference TranscriptMay 10, 2022
- 4D Molecular Therapeutics Inc 4D-310 Phase 1/2 and 4D-110 Phase 1/2 Clinical Data Update Call TranscriptOct 25, 2021
4D Molecular Therapeutics Inc 4D-150 Phase 2 PRISM Clinical Data Call Transcript
Ladies and gentlemen, thank you for standing by and welcome to 4D Molecular Therapeutics webcast presentation of interim data from the 4D-150 Phase 2 PRISM dose expansion cohort in wet AMD patients with severe disease activity and high treatment burden. (Operator Instructions)
As a reminder, today's call is being recorded. With that, I will hand the call over to Uneek Mehra, Chief Financial and Business Officer, who will make introductory comments.
Thank you, operator, and welcome to our webcast. We issued a press release describing the 4D-150 PRISM clinical trial interim results on Saturday, February 3. And the recording of this webcast will be accessible in the Investors section of the 4DMT website after the completion of this call today.
With me today are Dr. David Kirn, our Co-Founder and Chief Executive Officer; Dr. Bob Kim, our Chief Medical Officer; and Dr. Arshad Khanani from Sierra Eye Associates and a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)